Updated federal regulations are an essential step, but more work remains
Test advocates awaiting more details from CMS on its coverage policy
Recent developments of interest in cardiovascular medicine
Panelists acknowledge difficulty generating stronger data in ultra-rare disease
Agency appears unswayed by mitochondria-targeting drug for rare cardioskeletal disease
Only a minority of patients adhered to SUNTRAC screening recommendations